Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Liz Ann Sonders, the Chief Investment Strategist at Charles Schwab & Co. (NYSE: SCHW) highlighted certain unusual divergenc...
Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of ...
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease prog...
Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f...
Stifel analyst Paul Matteis downgrades Vigil Neuroscience (NASDAQ:VIGL) from Buy to Hold and lowers the price target from $1...
HC Wainwright & Co. analyst Andrew Fein downgrades Vigil Neuroscience (NASDAQ:VIGL) from Buy to Neutral and lowers the p...
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in prema...
